Affiliation:
1. Gastroenterology and Hepatology Research Center Isfahan University of Medical Sciences Isfahan Iran
2. Department of Infectious Diseases, School of Medicine Isfahan University of Medical Sciences Isfahan Iran
3. Department of Biostatistics and Epidemiology, School of Health Isfahan University of Medical Sciences Isfahan Iran
4. Nosocomial Infection Research Center Isfahan University of Medical Sciences Isfahan Iran
5. Cancer Prevention Research Center Isfahan University of Medical Sciences Isfahan Iran
Abstract
AbstractBackgrounds and AimsThis controlled randomized clinical trial was designed to compare effectiveness, side effects, and severity of symptoms before and after therapy between quadruple (QT) and sequential regimens (SQ) for Helicobacter Pylori (H. pylori).MethodsPatients were randomly allocated into two groups. Group A received a 14‐day QT including pantoprazole 40 mg q12 h, bismuth subcitrate 240 mg q12 h, clarithromycin 500 mg q12 h, and amoxicillin 1000 mg q12 h and group B received ST including pantoprazole 40 mg q12 h and amoxicillin 1000 mg q12 h for the initial 5 days followed by pantoprazole 40 mg q12 h, clarithromycin 500 mg q12 h and tinidazole 500 mg q12 h for the next 5 days. Adverse drug reactions and patients' compliance were assessed after finishing the treatment course and also 4 weeks after. All patients were naive, therefore ST and QT were first‐line therapies. To evaluate severity of symptoms we used Short‐Form Leeds Dyspepsia Questionnaire (SF‐LDQ) before taking the first dose of regimens, at the end of therapy, and also 4 weeks after (follow‐up).ResultsThe mean age in Group A (n = 83) was 48.55 ± 12.56 and 47.24 ± 12.78 in Group B (n = 79). No statistically significant differences were observed between the two groups regarding age, gender, endoscopic findings, and also eradication rate. The analysis demonstrated a significant decrease in SF‐LDQ score between baseline and after therapy and baseline and follow‐up in both regimen groups. Both regimens were well tolerated by the majority of patients, and there were no significant differences between the two groups in terms of adverse drug reactionsConclusionThis study showed that ST can be used as an alternative first‐line therapy to QT in patients with H. pylori infection.
Funder
Isfahan University of Medical Sciences
Reference25 articles.
1. Clinical assessment of the relationship of Helicobacter pylori to gastroduodenal pathologies. A prospective analysis of 253 consecutive patients;Cammarota G;Panminerva Med,1995
2. Helicobacter pyloriInfection
3. Risk factors in gastric cancer;Compare D;Eur Rev Med Pharmacol Sci,2010
4. Culture-guided treatment approach forHelicobacter pyloriinfection: Review of the literature
5. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report